This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2011 by Vancouver Coastal Health.
Recruitment status was:  Not yet recruiting
Information provided by:
Vancouver Coastal Health Identifier:
First received: June 13, 2011
Last updated: NA
Last verified: June 2011
History: No changes posted
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.

Condition Intervention Phase
Pheochromocytoma Neuroblastoma Paraganglioma Medullary Thyroid Carcinoma Carcinoid Tumors Drug: 123I-meta-iodobenzylguanidine Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Diagnostic

Resource links provided by NLM:

Further study details as provided by Vancouver Coastal Health:


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the presence, extent, or status of neuroendocrine tumors;
  • subjects must be able and willing to comply with study procedures.

Exclusion Criteria:

  • Subjects with history of renal insufficiency (serum creatinine level > 3.0 mg/dL [265 µmol/L]) and inability to be withdrawn from medications known to interfere with 123I-MIBG uptake;
  • Subjects unable to tolerate lying supine;
  • Subjects pregnant or breastfeeding, unless the information to be gained outweighs the possible hazardous effects of 123I-MIBG administration. Where the assessment of the risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the breastfeeding should be discontinued for at least 48 hours post-injection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01373736

Contact: Daniel Worsley, MD 604-875-4629

Canada, British Columbia
Vancouver Coastal Health
Vancouver, British Columbia, Canada, V5Z1M9
Sponsors and Collaborators
Vancouver Coastal Health
Principal Investigator: Daniel Worsley, MD Vancouver Coastal Health
  More Information

Responsible Party: Daniel Worsley, Vancouver Coastal Health Identifier: NCT01373736     History of Changes
Other Study ID Numbers: H10-02695
Study First Received: June 13, 2011
Last Updated: June 13, 2011

Additional relevant MeSH terms:
Carcinoid Tumor
Neuroendocrine Tumors
Thyroid Neoplasms
Carotid Body Tumor
Carcinoma, Neuroendocrine
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Endocrine System Diseases
Thyroid Diseases
Paraganglioma, Extra-Adrenal
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Radiopharmaceuticals processed this record on September 21, 2017